Oxidative Medicine and Cellular Longevity / 2022 / Article / Tab 1 / Research Article
Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy Table 1 The baseline characteristics of the participants (
Variables Total ( Breast cancer ( Endometrial cancer ( Ovarian cancer ( Age (years) <0.001 Smoking, 95 (0.9%) 68 (0.9) 12 (0.9) 15 (1.1) 0.671 Drinking, 44 (0.4) 36 (0.5) 5 (0.4) 3 (0.2) 0.445 SBP (mmHg) <0.001 DBP (mmHg) <0.001 BMI (kg/m2 ) <0.001 HTN, 1767 (16.5) 1149 (14.4) 341 (24.8) 277 (20.2) <0.001 CHD, 482 (4.5) 375 (4.7) 50 (3.6) 57 (4.2) 0.177 HF, 129 (1.2) 94 (1.2) 12 (0.9) 23 (1.7) 0.140 AF, 117 (1.1) 87 (1.1) 17 (1.2) 13 (0.9) 0.770 DM, 927 (8.6) 622 (7.8) 184 (13.4) 121 (8.8) <0.001 Stroke, 226 (2.1) 182 (2.3) 14 (1.0) 30 (2.2) <0.001 Dyslipidemia 6739 (62.8) 4896 (61.3) 919 (66.8) 924 (67.5) <0.001 TC (mmol/L) <0.001 TG (mmol/L) <0.001 LDL-C (mmol/L) <0.001 HDL-C (mmol/L) <0.001 Non-HDL-C (mmol/L) <0.001 FPG (mmol/L) <0.001 SUA (μ mol/L) <0.001 Creatinine (μ mol/L) <0.001 Lipid-lowering agents, 1196 (11.1) 978 (12.2) 103 (7.5) 115 (8.4) <0.001 Diuretics 1422 (13.3) 885 (11.1) 125 (9.1) 412 (30.1) <0.001 ACEI/ARB 1074 (10.0) 777 (9.7) 168 (12.2) 129 (9.4) <0.013 β -Blockers1160 (10.8) 872 (10.9) 122 (8.9) 166 (12.1) <0.019 CCB 2134 (19.9) 1501 (18.8) 349 (25.4) 284 (20.7) <0.001 FHS risk, low 6663 (62.1) 5096 (63.8) 696 (50.6) 871 (63.6) <0.001 Moderate 3020 (28.1) 2164 (27.1) 480 (34.9) 376 (27.5) High 1048 (9.8) 727 (9.1) 199 (14.5) 122 (8.9)
AF: atrial fibrillation; CHD: coronary heart disease; DM: diabetes mellitus; DBP: diastolic blood pressure; FHS: Framingham Heart Study; FPG: fasting plasma glucose; HDL-C: high-density lipoprotein cholesterol; HF: heart failure; HTN: hypertension; LDL-C: low-density lipoprotein cholesterol; non-HLD-C: non-high-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TC: total cholesterol; TG: triglycerides.
